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Mutations in the exons of the cyclin-dependent kinase inhibitor gene CDKN2A are melanoma-predisposition alleles
which have high penetrance, although they have low population frequencies. In contrast, variants of the melano-
cortin-1 receptor gene, MC1R, confer much lower melanoma risk but are common in European populations. Fifteen
Australian CDKN2A mutation–carrying melanoma pedigrees were assessed for MC1R genotype, to test for possible
modifier effects on melanoma risk. A CDKN2A mutation in the presence of a homozygous consensus MC1R
genotype had a raw penetrance of 50%, with a mean age at onset of 58.1 years. When an MC1R variant allele
was also present, the raw penetrance of the CDKN2A mutation increased to 84%, with a mean age at onset of
37.8 years ( ). The presence of a CDKN2A mutation gave a hazard ratio of 13.35, and the hazard ratioPp .01
of 3.72 for MC1R variant alleles was also significant. The impact of MC1R variants on risk of melanoma was
mediated largely through the action of three common alleles, Arg151Cys, Arg160Trp, and Asp294His, that have
previously been associated with red hair, fair skin, and skin sensitivity to ultraviolet light.
Introduction
To date, germline mutations in three different genes have
been shown to influence risk of melanoma: cyclin-de-
pendent kinase inhibitor 2A (CDKN2A [MIM 600160])
(Hussussian et al. 1994; Kamb et al. 1994a), cyclin-
dependent kinase 4 (CDK4 [MIM 123829]) (Zuo et al.
1996; Soufir et al. 1998), and the melanocortin-1 re-
ceptor (MC1R [MIM 155555]) (Palmer et al. 2000). The
basis of melanoma risk as determined by these genes
probably revolves around at least two independent path-
ways (Whiteman et al. 1998), one being the CDKN2A/
CDK4 cell-cycle and tumor-suppressor gene axis, and
the other a pigmentation-associated predisposition axis
implicated by the recent association of MC1R variants
with red hair, fair skin, freckling, and melanoma (Palmer
et al. 2000). Melanoma risk attributable to MC1R may
arise through the action of solar ultraviolet (UV) light
on lighter skin tones with diminished tanning capacity
(Bliss et al. 1995; Breitbart et al. 1997) or, possibly,
through a more direct intrinsic effect on melanocytic
cellular transformation. On the other hand, linkage to
the 9p21-22 region containing CDKN2A (Zhu et al.
1999) of a quantitative trait locus accounting for 33%
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of variance in flat mole count suggests that CDKN2A
mutation may play a role in determination of mole den-
sity which, in turn, predisposes to later melanoma for-
mation; this appears to be a risk factor quite distinct
from the red hair and fair skin associated with MC1R
variants (Garbe et al. 1994; Bliss et al. 1995; Grange et
al. 1995; Grulich et al. 1996).
The p16INK4A protein encoded by the CDKN2A locus
(Kamb et al. 1994b;Nobori et al. 1994) acts as a tumor
suppressor that induces G1 cell-cycle arrest by binding
to and inhibiting the kinase activities associated with
cyclin D complexes with cyclin-dependent kinases 4 and
6 (CDK4 and CDK6). G1-S phase transition is usually
dependent upon phosphorylation of the retinoblastoma
protein (pRB) by the cyclin D1/CDK4 complex (Serrano
et al. 1993; Lukas et al. 1995). Inactivation of CDKN2A
via one of several mechanisms (homozygous deletion,
mutation, and/or promoter methylation) is a frequent
event in tumors of many types (e.g., see reports by Kamb
et al. [1994a] and Nobori et al. [1994]; reviewed by
Ruas and Peters [1998]). Furthermore, the presence of
mutations at this locus in the germline of a small pro-
portion of familial melanoma patients (e.g., see reports
by Hussussian et al. [1994] and Kamb et al. [1994b];
reviewed by Hayward [1998]) indicates that p16 in-
activation is an early and possibly an initiating step in
melanoma tumorigenesis.
MC1R is a seven-pass transmembrane G-protein–
coupled receptor, expressed in skin melanocytes, that
activates adenylate cyclase to elevate cyclic adenosine
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monophosphate levels upon stimulation by the proopio-
melanocortin-derived peptides a-melanocyte-stimulating
hormone (a-MSH) and adrenocorticotropic hormone
(Thody and Graham 1998). Hormonal stimulation of
MC1R leads to eumelanogenesis and is central to the
tanning response of human skin after UV irradiation (Su-
zuki et al. 1999). During UV exposure of the skin, there
is an increase in melanin production that may occur, in
part, via an increase in tyrosinase gene transcription and
enzyme activity (Gilchrest et al. 1996; Sturm et al. 1998).
MC1R also regulates the balance of two distinct melanin
types, the red/yellow pheomelanin and black/brown eu-
melanin; this regulation, in turn, forms the basis of the
association between specific MC1R alleles and red hair
and fair skin (Valverde et al. 1995; Box et al. 1997; Smith
et al. 1998; Flanagan et al. 2000; Palmer et al. 2000;
Bastiaens et al. 2001). It has already been shown that
three common MC1R variant alleles, Arg151Cys,
Arg160Trp, and Asp294His, are associated with an in-
creased risk of melanoma within the Queensland pop-
ulation; this risk is mediated, at least in part, by an effect
on pigmentation phenotype (Palmer et al. 2000).
Germline mutations in CDKN2A have been identified
in only a small proportion of the 5%–10%ofmelanoma
cases that occur in multiplex families. A recent popu-
lation-based assessment of the overall caseload of mel-
anoma in Queensland estimated that ∼0.2% of all mel-
anomas may be attributed to germline mutation of this
gene (Aitken et al. 1999). Within the high-UV environ-
ment of Queensland, penetrance for melanoma is vir-
tually 100% by 80 years of age for those individuals
carrying a germline CDKN2A mutation (D.T. Bishop,
F. Demenais, A.M. Goldstein, W. Bergman, J.N. Bishop,
B.B. de Paillerets, A. Chompret, P. Ghiorzo, N. Gruis,
J. Hansson, M. Harland, N. Hayward, E.A. Holland,
G.J. Mann, M. Mantelli, D. Nancarrow, A. Platz, M.A.
Tucker, the Melanoma Genetics Consortium [“Bishop
et al.”], unpublished data). Mutations within the CDK4
gene are even less frequent than those within CDKN2A
(Hayward 1999). On the other hand, MC1R variants
have been identified at a much higher frequency but
with much lower genotype relative risk for melanoma
(Box et al. 1997; Smith et al. 1998; Palmer et al. 2000).
Nevertheless, because of the high frequency of MC1R
variants in melanoma cases (Palmer et al. 2000), we
estimated that as many as one third of melanomas in
Queensland may be attributable to MC1R genotype.
The purpose of the present study was to determine
whetherMC1R variants modify penetrance of CDKN2A
mutations that occur in a subset of multiplex melanoma
families. Affected and unaffected members of 15 multi-
plex families with melanoma were available for this anal-
ysis, with each family segregating one of a total of nine
different CDKN2Amutations (Walker et al. 1995; Flores
et al. 1997; Whiteman et al. 1997; Aitken et al. 1999).
Subjects and Methods
Ascertainment of Samples and DNA Extraction
The fifteen melanoma pedigrees available for the pre-
sent analysis were identified as part of the Queensland
Familial Melanoma Project (Aitken et al. 1996). In brief,
extent of family history was determined in a total of
1,897 families ascertained as a subset of the 12,006 in-
cident cases of histologically confirmed cutaneous mel-
anoma that were diagnosed in residents of Queensland
during the period of 1982–1990 and were reported to
the Queensland Cancer Registry. The standardized fam-
ily risk index, described by Aitken et al. (1996, 1999),
was used to divide the total sample of 1,897 families
into three strata of familial melanoma risk, including
1,392 low-risk, 414 intermediate-risk, and 91 high-risk
families. Blood was collected and DNA extracted from
members of selected families, as described elsewhere
(Aitken et al. 1999). Extensive genotyping for CDKN2A
germline mutations has resulted in identification of a
total of 15 kindreds, all identified as high-risk, who con-
tain a total of nine different CDKN2A mutations:
Gln50Arg, Arg24Pro, 46delC, Leu32Pro, Asp108Asn,
Leu16Pro, Gly35Ala, 9del24, 33ins24, or Met53Ile
(Walker et al. 1995; Flores et al. 1997; Whiteman et al.
1997; Aitken et al. 1999).
Measures
An ongoing part of the family ascertainment proce-
dure involved submission of questionnaires about stan-
dard melanoma risk factors, including propensity to
burn in the sun, pigmentation (skin color at age 21 years
and eye color), total freckling in summer, and density of
melanocytic nevi. Data were also collected on age at
onset of melanoma, number of primary tumors, other
tumors of nonmelanocytic origin, and ancestry.
MC1R Genotyping
To obtain sufficient DNA product for sequencing and
allele-specific oligonucleotide (ASO) dot-blot detec-
tion of nine previously identified MC1R variants, in-
cluding Val60Leu, Asp84Glu, Val92Met, Arg142His,
Arg151Cys, Ile155Thr, Arg160Trp, Arg163Gln, and
Asp294His, a nested-primer PCR strategy was used, as
described elsewhere (Box et al. 1997), for amplification
of extracted genomic DNA from the families with mel-
anoma. The first primer set, hMC1R N-outer and C-
outer (Box et al. 1997), was used in a 25-ml Taq DNA
polymerase amplification reaction containing ∼25 ng
of genomic DNA, 1# PCR buffer containing 20 mM
Tris-HCl and 50 mM KCl (Promega), 10% dimethyl-
sulfoxide (Dutton et al. 1993), 1.5 mMMgCl2, 25 pmol
of each primer (C-outer and N-outer), 200 mM of each
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dNTP, and 1.25 U of Taq DNA polymerase (Promega).
The reaction was initially denatured for 3 min at 94C,
followed by 34 cycles of 1 min at 94C, 1 min at 55C,
and 2 min at 72C, concluding with a 7-min extension
at 72C. Five microliters of the first-round reaction was
used as a template to seed a second 25-ml reaction,
which used 25 pmol each of the N-inner and C-inner
primer pairs (Box et al. 1997). Amplification conditions
were identical to those in the first round. The ampli-
fication product was used for either direct sequencing
or ASO dot-blot analysis (Palmer et al. 2000; Box et
al. 2001).
All of the family members who had developed mel-
anoma by the time of this analysis, as well as a total of
50 unaffected individuals selected from the pedigrees,
were genotyped by complete nucleotide sequencing to
determine MC1R variant content within the families.
Automated sequencing of the MC1R coding region was
performed by the addition of 100–200 ng of DNA tem-
plate to 8 ml of ABI Prism dye terminator premix (util-
izing AmpliTaqDNA polymerase FS [Perkin Elmer]) and
3.2 pmol of primer. MilliQ water was added to make
the final volume 20 ml, and the entire reaction mixture
was then covered with paraffin oil. Cycling was per-
formed on a Thermal Cycler Model 480 (Perkin Elmer)
using standard cycling conditions: 30 s at 96C, 15 s at
50C, and 4 min at 60C, for 25 cycles. PCR reaction
products were ethanol precipitated, were dried for 1 min
at 95C, and were submitted to an ABI 373 automated
sequencer. Sequence data were analyzed utilizing the Se-
quencher program (Genecodes).
The remaining family members were MC1R geno-
typed using a dot-blotting procedure described elsewhere
(Palmer et al. 2000). Denatured inner PCR reaction
product was blotted onto Magna (MSI) nylon transfer
membrane and was cross-linked under 150 mJ of UV
energy. After this, the blot was prehybridized in 10 ml
of tetramethyl ammonium chloride (TMAC) hybridi-
zation buffer, which contained 3 M TMAC, 1 mM
EDTA, 25 mM Na3HPO4 pH 6.8, 0.1% SDS, 5# Den-
hardt’s solution, and 0.1 mg/ml sonicated salmon sperm
DNA for 1 h at 42C. After the addition of 50–100 ml
of the g-[32P]-radiolabelled probe, dot blots were left to
hybridize overnight at 42C. Unbound probe was re-
moved by washing for 20 min at 50C in 10ml of TMAC
wash buffer, consisting of 3 M TMAC, 1 mM EDTA,
25 mM Na3HPO4, and 0.1% SDS. Genotypes were vi-
sualized using autoradiography.
Statistical Methods
Survival analysis was performed using the Survival 5
package of Therneau (1999), running on statistics pack-
age R, version 1.1.1. If MC1R and CDKN2A genotypes
are the sole or overwhelming causes of melanoma in
these families, then analyses including these variables
will eliminate problems caused by the correlated (i.e.,
familial) nature of the data. However, if other familial
factors are acting to increase risk, these may confound
the detection of effects of MC1R. We therefore per-
formed Cox proportional-hazards model analyses, strat-
ifying on pedigree or nuclear family and also including
family as a clustering variable in a gamma frailty model,
in an attempt to control for residual familial correlation
in risk of melanoma. Stratifying on nuclear families and
restricting the analysis to only siblings is equivalent to
the “sib-TDT” (Spielman and Ewens 1996) method of
adjusting for population stratification. A Cox propor-
tional-hazards model was also used to generate the sur-
vival curve showing age-specific probability of mela-
noma development for the Queensland population at
large, using all cases of invasive melanoma reported to
the Queensland Cancer Registry in 1996.
Results
There were 15 familial melanoma pedigrees available for
the present study, in which nine different CDKN2A mu-
tations were segregating (table 1). The families contained
a total of 53 sibships and 270 individuals, with an av-
erage of 6.5 melanoma cases per kindred. The number
of members for whom DNA or genotype information
was available is shown in table 2. MC1R genotype was
determined in 136 family members, and CDKN2A ge-
notype was available for 162 individuals; however, only
131 of these individuals have both loci genotyped. There
were 97 individuals with melanoma within the sample,
76 of whom were found to carry a CDKN2A mutation.
Ten (10%) were designated as having sporadic mela-
noma, on the basis of the absence of any CDKN2A
mutation; these 10 include one case each in pedigrees
40599, 40750, 40823, 41031, and 41162, two cases in
pedigree 41105, and three in pedigree 60001. CDKN2A
mutation data were not available for 11 cases (table 1).
There was a total of 60 pedigree members with recorded
skin color and 57 with recorded hair color.
Allele frequencies for the eight MC1R variants de-
tected in family members are shown in table 3, together
with frequency data from two samples of control in-
dividuals drawn from the general population (Palmer
et al. 2000). The variant frequencies were similar to
those observed in the southeastern Queensland popu-
lation, except for the frequency of the Arg151Cys var-
iant; this variant is present in ∼26% of family members
but has a general population frequency of ∼10%. This
difference is explained by the high degree of Celtic an-
cestry of the families (Aitken et al. 1999), since the
Celtic population is one in which the Arg151Cys allele
is known to be overrepresented (Smith et al. 1998).Only
14% of those genotyped did not carry an MC1R var-
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Table 1
Kindreds with Melanoma
PEDIGREE
ID
NO. OF
MEMBERS
CDKN2A
MUTATION
NO. WITH MELANOMA STATUS
NO. OF
SPOUSESAffected Unaffected Unknown
40300 17 R24Pa 8 7 2 3
40582 24 33ins24b 6 16 2 3c
40599 30 Q50Rd 12 17 1 4
40750 20 G35Ad 5 15 0 2
40787 18 46delCe 6 12 0 3
40823 14 L32Pd 6 8 0 2c
40935 10 L16Pd 3 5 0 1
41001 27 M53Ia 11 16 0 5
41019 8 R24Pa 2 6 0 1
41031 19 M53Ia 5 14 0 2
41105 23 D108Nd 4 19 0 2
41119 12 33ins24b 7 5 0 2
41156 4 M53Ia 2 0 2 2
41162 8 M531a 3 1 4 0
60001 38 M53Ia 17 21 0 7
Totals 270 97 162 11 39
a Determined by Monzon et al. (1998) to be a nonfunctional variant.
b Functional significance uncertain (see report by Monzon et al. [1998]).
c Pedigree contains one spouse who has developed melanoma.
d Functional consequence not assessed.
e Frameshift mutation expected to lead to a nonfunctional protein.
Table 2
Genotyped Family Members Available for Analyses
LOCUS AND
GENOTYPEa
NO. OF
INDIVIDUALS
NO. WITH MELANOMA STATUS
Affected Unaffected Unknown
CDKN2A:
Wild typeb 68 10 58 0
Mutant 94 76 18 0
NA 108 11 86 11
MC1R:
Consensusc 20 5 15 0
One variant 58 28 30 0
Two variants 58 34 24 0
NA 134 30 93 11
a NA p not available.
b Wild type for CDKN2A at each of Gln50Arg, Arg24Pro, 46delC,
Leu32Pro, Asp108Asn, Leu16Pro, Gly35Ala, 9del24, 33ins24, and
Met53Ile positions.
c Consensus genotype at each of the Val60Leu, Asp84Glu,Val92Met,
Arg142His, Arg151Cys, Ile155Thr, Arg160Trp, Arg163Gln, and
Asp294His positions.
iant, and, notably, all of the seven individuals with spo-
radic melanomas (CDKN2A-mutation negative) for
whom MC1R genotype was available carried variants.
To maximize the available information regarding skin
and hair color, association with MC1R variants was
tested with simple grouping of all study members, ir-
respective of pedigree or relationship. When all MC1R
variants were grouped, there was a significant tendency
forMC1R variants to increase in frequency as hair color
lightened and became red (Mantel-Haenszel test for
trend ). This was more marked when the threePp .01
previously defined red hair color (RHC) variants,
Arg151Cys, Arg160Trp, and Asp294His (Box et al.
2001), were pooled ( ). A similar trend was ob-P ! .001
served with skin color, although all variants considered
together were not significantly associated with skin
color, and the association between skin color and RHC
variants was marginal ( ). CDKN2A mutationsPp .03
showed no association with skin or hair color in this
data set.
The unstratified survival analysis that included
MC1R and CDKN2A consensus homozygotes versus
those individuals with one or more variants (table 4)
showed that the presence of an MC1R variant allele
significantly increased the risk of melanoma develop-
ment in both CDKN2A carriers and noncarriers (Pp
). The impact on melanoma risk of carrying both.005
an MC1R variant and a CDKN2A mutation is dem-
onstrated by a significant increase in raw penetrance
(shown as a percentage of melanoma cases) from 50%
to 84%, and a decrease in the mean age at onset from
58.1 to 37.8 years, when compared with family mem-
bers who carry a CDKN2A mutation alone ( ).Pp .01
There was little difference in risk of melanoma between
family members carrying one versus two variant MC1R
alleles (odds ratio [OR] 3.3, 95% confidence interval
[CI] 1.25–8.59; OR 3.4, 95% CI 1.31–8.78, respec-
tively, using MC1R consensus genotype as the reference
category).
Multiple tumors were common among individuals
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Table 3
Frequencies of MC1R Variants in 136 Typed Individuals
VARIANT
FREQUENCY IN
Families with
Melanoma
Population Sample 1
( )anp 390
Population Sample 2
( )bnp 1,627
Val60Leu .109 .120 .124
Asp84Glu .011 .015 .011
Val92Met .109 NA .097
Arg142His .000 NA .009
Arg151Cysc .255 .089 .111
Ile155Thr .007 NA .010
Arg160Trp .084 .076 .071
Arg163Gln .051 NA .050
Asp294His .011 .031 .028
a Frequency estimated in an unselected sample of 390 haplotypes from southeastern Queens-
land, presented by Palmer et al. (2000). NA p not available.
b Frequency estimated in a second unselected sample of 1,627 haplotypes from southeastern
Queensland (D.L. Duffy, N.F. Box, W. Chen, A. Green, N.G. Martin, R.A. Sturm, unpublished
data).
c .P ! .001
with melanoma in these families who carried a
CDKN2A mutation (70%), but they were seen in only
one of seven who did not. There was a trend for case
individuals without a CDKN2A mutation who carried
the MC1R consensus genotype to have fewer tumors,
but the numbers in this group (with information avail-
able) are small (1/4 vs. 35/50).
The Cox proportional-hazard method was also used
to assess the influence, of both the CDKN2A mutation
and the MC1R variants, on propensity to develop mel-
anoma (table 5). Family members carrying a CDKN2A
mutation were 13.35-fold (95% CI 6.01–29.67) more
likely to developmelanomas thanwere those individuals
who carried the wild type. Carriage of any MC1R var-
iant significantly increased the likelihood of melanoma
development in these pedigrees, 3.72-fold (95% CI
1.48–9.37). Stratification on sex caused the hazard ra-
tios to demonstrate an unusual tendency for more fe-
males than males to develop melanoma, although this
tendency was not significant. The analyses that included
pedigree as a covariate obtained parameter estimates
(MC1R OR 4.7, 95% CI 1.1–19.9) similar to those
shown in table 5, as did those conditioning on pedigree
(MC1R OR 3.3, 95% CI 0.70–16.0), though the latter
led to a loss of power reflected in a nonsignificant P
value. Stratification on sibship reduced the sample size
and broadened the CI still further. The frailty models
using pedigree and sibship as clustering variables esti-
mated the frailty variance as not significantly different
from zero, suggesting that there were no large residual
familial correlations that might confound the estimates
of the effects of CDKN2A and MC1R.
When the Cox proportional-hazard analysis was re-
stricted to either the Arg151Cys variant (the most com-
mon allele in these kindreds) or to the combination of
the RHC variants, similar parameter estimates were ob-
tained, but they were less significant than when all
MC1R variants were pooled (for Arg151Cys, OR 1.48,
95% CI 0.91–2.42; for the RHC variants, OR 2.02,
95% CI 1.16–3.12). Grouping of the MC1R variants
other than the three major variants that are important
in hair and skin color determination gave a hazard ratio
of 1.32 (table 5), which was not significantly different
from the hazard ratio for those individuals carrying a
consensus MC1R genotype, indicating that most of the
effect of MC1R genotype on melanoma risk is due to
the Arg151Cys, Arg160Trp, and Asp294His alleles.
There were only 14 MC1R heterozygous parents of af-
fected children available for analysis, and the transmis-
sion/disequilibrium test result was not significant (9/14
variant alleles transmitted; ).Pp .42
Since we detected no significant confounding effect
of pedigree membership, we have summarized the re-
sults from the unstratified Cox proportional-hazards
model as the predicted survival curve for each of the
four genotype categories (fig. 1). These predicted curves
are parallel because of the assumed proportional-haz-
ards relationship and the absence of an interaction term
in the selected model. For comparison, the age-specific
probabilities of melanoma development within the
Queensland population at large are also shown; despite
the small numbers in some subgroups, the estimates of
risk associated with the MC1R and CDKN2A “wild-
type” genotype are close to those for the general
population.
Discussion
The present study extends our previously reported as-
sociation of MC1R gene variants with melanoma (Pal-
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Table 4
Mean Disease-Free Survival, by CDKN2A and MC1R Genotype
Genotype
(CDKN2A, MC1R)a
No. of
Individuals
No. of Melanoma
Cases (%)
Mean Age at Onset  SE
(years)
0, 0 10 0 (.0) …
0, 1 45 7 (15.6) 82.4  3.90
1, 0 10 5 (50.0) 58.1  7.23
1, 1 68 57 (83.8) 37.8  1.75
a “0” indicates wild type CDKN2A or consensus MC1R at all positions analyzed. An
MC1R value of “1” indicates one or two MC1R variants. Each CDKN2A mutation is carried
in heterozygote form. The P value for difference between CDKN2Ap1 group with and
without MC1R variant is .01
Table 5
Hazard Ratios for CMM versus CDKN2A
Genotype, MC1R Genotype, and Sex, Calculated
by the Cox Proportional-Hazards Method
Risk Factor Hazard Ratio 95% CI
CDKN2A mutanta 13.35 6.01–29.67
MC1R variantb: 3.72 1.48–9.37
RHC variant 2.02 1.16–3.12
Other variantc 1.32 .88–1.98
Female sex 1.48 .92–2.40
a Each CDKN2A mutation is carried in hetero-
zygote form.
b Members carrying 1 or 2 variants considered
together in this analysis.
c Other MC1R variants defined for this analysis
as Val60Leu, Asp84Glu, Val92Met, Ile155Thr, and
Arg163Gln.
mer et al. 2000), by demonstrating a significant impact
of MC1R genotype on penetrance of CDKN2A muta-
tions in melanoma-dense pedigrees. The presence of an
MC1R variant in addition to a CDKN2A mutation sig-
nificantly increased the raw melanoma penetrance, de-
creasing age at onset by up to 20 years compared with
individuals carrying a CDKN2A mutation alone. At age
50 years, 81% of people with both a CDKN2Amutation
and an MC1R variant had developed melanoma,
whereas only 57% of those carrying a CDKN2A mu-
tation alone had developed melanoma. The presence of
an MC1R variant alone was estimated to account for a
risk of 14% by age 50 years. Although there were no
melanoma cases without either CDKN2A mutations or
MC1R variants, the Cox proportional-hazards model
predicted an overall melanoma risk for this genotype of
∼10% by age 70 years, close to the Queensland popu-
lation lifetime melanoma risk, previously estimated at
∼1 in 7. Penetrance of CDKN2A mutations, without
regard to MC1R status, has been estimated at ∼58% by
age 80 years in the United Kingdom, at ∼76% in North
America, and at ∼92% by the same age in Australia
(Bishop et al., unpublished data). The presence of a sub-
stantially higher environmental UV level within Austra-
lia has been suggested to account for this increase in
penetrance of CDKN2A mutations.
Frailty-variance estimates were not significantly dif-
ferent from zero when both pedigree and sibship were
used as clustering variables, suggesting that the effects
of CDKN2A and MC1R together may account for the
majority of melanoma cases within these pedigrees. No
significant differences in trends in individual pedigrees
were observed in the survival analyses, suggesting that
individual CDKN2A mutations in these families tend
to have similar effects on melanoma penetrance, al-
though power to detect such differences is low. At pre-
sent, there is a dearth of studies that assess differences
in melanoma penetrance in families carrying different
CDKN2A mutations, and it can only be assumed that
each CDKN2A mutation is acting similarly to increase
risk of melanoma. It is clear that future attempts to
assess more accurately the individual and combined im-
pact of CDKN2A mutations on melanoma incidence
will require knowledge of MC1R genotype status,
which is demonstrated here to act as a significant mod-
ifier of CDKN2A penetrance. Tumor types other than
melanoma were not overrepresented in this cohort of
pedigrees (N.K. Hayward and J.M. Palmer, unpublished
data), although other cohorts of families have been
shown to have a significant excess of pancreatic cancers
(Goldstein et al. 1995; Vasen et al. 2000).
Unlike CDKN2A mutations, MC1R variants clearly
do not show functional equivalence in their influence
on melanoma risk. The RHC variants, Arg151Cys,
Arg160Trp, and Asp294His, account for much of the
MC1R effect in increasing CDKN2A penetrance, with
the remaining variants not significantly associated with
melanoma risk. The same three RHC variants are those
identified in association with fair skin, freckling, poor
tanning capacity, melanoma, and nonmelanocytic skin
cancer risk (Box et al. 1997; Smith et al. 1998; Flanagan
et al. 2000; Palmer et al. 2000; Bastiaens et al. 2001;
Box et al. 2001). Limited information on pigmentation
phenotype was available for the family members in-
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Figure 1 Expected survival curves (Cox proportional-hazards model) for melanoma versus CDKN2A and MC1R genotypes. For clarity,
the lines joining the points of the empirical survivor functions (black diamonds [] denote CDKN2AmutationMC1R variant; white diamonds
[] denote CDKN2A mutation  MC1R wt; white triangles [] denote CDKN2A wt  MC1R variant) have been omitted.
cluded in the present study, which prevented a more
thorough analysis of this factor’s interactions with
MC1R variants, CDKN2A mutations, and melanoma.
It is an interesting parallel that the presence of an
MC1R variant shifts the age-specific CDKN2A muta-
tion penetrance curve towards younger ages in a way
similar to that observed for those families ascertained
in a high-UV environment (Bishop et al., unpublished
data). MC1R activity is crucial for an effective skin
response to UV exposure, as assessed by visible tanning,
and carrying a single RHC MC1R variant is enough to
significantly diminish the skin’s capacity to respond in
a protective way to UV exposure (Flanagan et al. 2000;
Healy et al. 2000; Box et al. 2001). Our data suggest
that carrying two MC1R variants adds no further risk
than carrying one such variant, although a larger sample
may reveal a difference. It is clear from earlier studies
that the presence of a single RHC MC1R variant is
enough to give a significant heterozygote effect on pig-
mentation and melanoma risk (Healy et al. 2000; Pal-
mer et al. 2000) and may act here to shift the eumelanin/
pheomelanin balance and to increase the amount of
pheomelanin produced by the skin. Pheomelanin and
related metabolites have been shown to be mutagenic
and cytotoxic (Harsanyi et al. 1980; Sturm 1998), sug-
gesting a dual UV sensitivity where increased levels of
this type of melanin within the skin may not only have
a diminished UV protective capacity but may actively
promote generation of skin tumors. Alternatively, a sin-
gle MC1R variant may be enough to exert a marked
intrinsic and non–pigmentation-related effect on the
propensity for melanocytic cellular transformation.
In conclusion, we have presented evidence that var-
iant alleles at theMC1R locus significantly increase pen-
etrance of mutations at the CDKN2A locus; we believe
that this is one of the few good examples of effects of
gene-gene interaction on disease risk documented to
date, and it is supported by the accompanying study by
772 Am. J. Hum. Genet. 69:765–773, 2001
van der Velden et al. (2001 [in this issue]). One of the
major goals for researchers attempting to understand
the complexities of melanoma etiology is to identify host
factors that influence age at onset, number of primary
tumors, tumor site, and time to metastasis. Obtaining
reliable predictors of risk and prognosis offers the prom-
ise of better management and prevention of many tumor
types. This is nowhere more relevant than formelanoma
which, if caught early, is eminently treatable but has
very poor prognosis following metastasis.
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